The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
923
May 27, 1994
View Complete Issue         Table of Contents 2019 
Issue 923
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Fluvastatin for Lowering Cholesterol
May 27, 1994 (Issue: 923)
Fluvastatin (Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from previously available drugs in this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 923
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.